Podium to Practice: Chicago 2026 – BREAST: NATALEE

Podium to Practice: Chicago 2026 – BREAST: NATALEE

Podium to Practice: Chicago 2026

Studies / Trials Discussed

501 – Prognostic and predictive impact of baseline gene expression (exp) in the NATALEE trial of adjuvant (adj) ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in HR+/HER2− early breast cancer (EBC).

Icon Chair Speaker

Chair

Dr. Christine Simmons

Icon Chair Speaker

Speakers

Dr. Christine Brezden-Masley

Dr. Heather McArthur

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

501 – Prognostic and predictive impact of baseline gene expression (exp) in the NATALEE trial of adjuvant (adj) ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in HR+/HER2− early breast cancer (EBC).
Tagged